Valuation: CSL Limited

Market Cap 59.08B 50.71B 47.6B 43.47B 82.04B 5,635B 82.44B 563B 218B 2,843B 222B 217B 9,416B P/E 2027 *
20.3x
P/E 2028 * 18.4x
Enterprise Value 68.21B 58.54B 54.95B 50.19B 94.72B 6,506B 95.17B 650B 252B 3,282B 256B 251B 10,871B EV / Sales 2027 *
4.33x
EV / Sales 2028 * 4.17x
Free-Float
99.97%
Yield 2027 *
2.44%
Yield 2028 * 2.58%
1 day-0.69%
1 week+3.58%
Current month+40.13%
1 month+48.16%
3 months+77.96%
6 months+18.09%
Current year-0.12%
1 week 166.28
Extreme 166.28
175.97
1 month 114.26
Extreme 114.26
175.97
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap.
2/23/26 Free

Director

263 0.0001%
2/23/26 Free 512 0.0001%
2/19/26 Fiscal year

Director

183 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
-0.69%+3.58%-19.85%-35.64% 59.49B
-1.27%-2.10%+40.08%-0.93% 83.24B
-7.71%-15.36%+496.81%+29.66% 63.41B
+0.76%+3.53%+0.08%+36.18% 52.94B
-1.38%+1.47%+10.64%+168.92% 49.86B
+0.28%-0.05%+61.97%-16.45% 32.62B
-0.54%+0.46%+53.64%+99.07% 26.29B
+9.69%+13.61%+9.85%+224.85% 22.23B
-1.15%-0.30%+60.29%+121.68% 17.22B
-1.00%-4.67%+63.76%+179.14% 15.72B
Average -0.28%+18.14%+77.73%+80.65% 42.3B
Weighted average by Cap. -1.14%+26.23%+94.28%+52.00%

Financials

2027 *2028 *
Net sales 15.74B 13.51B 12.68B 11.58B 21.86B 1,501B 21.96B 150B 58.15B 757B 59.1B 57.81B 2,508B 16.28B 13.97B 13.11B 11.98B 22.6B 1,552B 22.71B 155B 60.13B 783B 61.11B 59.78B 2,594B
Net income 2.82B 2.42B 2.27B 2.07B 3.91B 269B 3.93B 26.87B 10.41B 136B 10.58B 10.35B 449B 3.16B 2.71B 2.54B 2.32B 4.38B 301B 4.4B 30.09B 11.66B 152B 11.85B 11.59B 503B
Net Debt 9.13B 7.84B 7.35B 6.72B 12.68B 871B 12.74B 87.03B 33.73B 439B 34.27B 33.53B 1,455B 8.73B 7.49B 7.03B 6.42B 12.13B 833B 12.18B 83.25B 32.26B 420B 32.79B 32.07B 1,392B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-08-26 A$172.44 -0.69% 1,014,011
26-08-25 A$173.64 +2.68% 1,212,519
26-08-24 A$169.11 +0.48% 1,138,160
26-08-21 A$168.30 -1.69% 2,686,531
26-08-20 A$171.20 +2.84% 3,463,800
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
123.59USD
Average target price
116.90USD
Spread / Average Target
-5.41%

Quarterly revenue - Rate of surprise